Fine-tuning the CAR spacer improves T-cell potency

OncoImmunology

Volumn 5, Issue 12, 2016, Pages

  Watanabe, Norihiro ^a   Bajgain, Pradip ^a   Sukumaran, Sujita ^a   Ansari, Salma ^a   Heslop, Helen E ^a   Rooney, Cliona M ^a   Brenner, Malcolm K ^a   Leen, Ann M ^a   Vera, Juan F ^a  

^a TEXAS CHILDREN S HOSPITAL   (United States)

Author keywords

CAR T cell; T cells

Indexed keywords

CD32 ANTIGEN; CD64 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; PROSTATE STEM CELL ANTIGEN; RETROVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL AGING; CELL MIGRATION; CELL PROLIFERATION; CHROMIUM RELEASE ASSAY; COCULTURE; CONTROLLED STUDY; EXPERIMENTAL NEOPLASM; FLOW CYTOMETRY; GENE OVEREXPRESSION; IN VIVO STUDY; LUMINESCENCE; MICROARRAY ANALYSIS; MOUSE; NONHUMAN; SENESCENCE; T LYMPHOCYTE; TUMOR LOCALIZATION; TUMOR VOLUME;

EID: 85007494702     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1253656     Document Type: Article

References (38)

1. Jensen MC, Riddell SR. Design and implementation of adoptive therapy with chimeric antigen receptor-modified T cells. Immunol Rev 2014; 257(1):127-44; PMID:24329794; http://dx.doi.org/10.1111/imr.12139
2. Dotti G, Gottschalk S, Savoldo B, Brenner MK. Design and development of therapies using chimeric antigen receptor-expressing T cells. Immunol Rev 2014; 257(1):107-26; PMID:24329793; http://dx.doi.org/10.1111/imr.12131
3. Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014; 371(16):1507-17; PMID:25317870; http://dx.doi.org/10.1056/NEJMoa1407222
4. Brentjens RJ, Riviere I, Park JH, Davila ML, Wang X, Stefanski J, Taylor C, Yeh R, Bartido S, Borquez-Ojeda O, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood 2011; 118(18):4817-28; PMID:21849486; http://dx.doi.org/10.1182/blood-2011-04-348540
5. Eshhar Z. The T-body approach:redirecting T cells with antibody specificity. Handb Exp Pharmacol 2008(181):329-42; PMID:18071952; http://dx.doi.org/10.1007/978-3-540-73259-4_14
6. Moritz D, Groner B. A spacer region between the single chain antibody- and the CD3 zeta-chain domain of chimeric T cell receptor components is required for efficient ligand binding and signaling activity. Gene Ther 1995; 2(8):539-46; PMID:8593604
7. Hombach A, Heuser C, Gerken M, Fischer B, Lewalter K, Diehl V, Pohl C, Abken H. T cell activation by recombinant FcepsilonRI gamma-chain immune receptors:an extracellular spacer domain impairs antigen-dependent T cell activation but not antigen recognition. Gene Ther 2000; 7(12):1067-75; PMID:10871757; http://dx.doi.org/10.1038/sj.gt.3301195
8. Almasbak H, Walseng E, Kristian A, Myhre MR, Suso EM, Munthe LA, Andersen JT, Wang MY, Kvalheim G, Gaudernack G, et al. Inclusion of an IgG1-Fc spacer abrogates efficacy of CD19 CAR T cells in a xenograft mouse model. Gene Ther 2015; 22(5):391-403; PMID:25652098; http://dx.doi.org/10.1038/gt.2015.4
9. Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR. The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity. Cancer Immunol Res 2015; 3(2):125-35; PMID:25212991; http://dx.doi.org/10.1158/2326-6066.CIR-14-0127
10. Jonnalagadda M, Mardiros A, Urak R, Wang X, Hoffman LJ, Bernanke A, Chang WC, Bretzlaff W, Starr R, Priceman S, et al. Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 2015; 23(4):757-68; PMID:25366031; http://dx.doi.org/10.1038/mt.2014.208
11. Overdijk MB, Verploegen S, Ortiz Buijsse A, Vink T, Leusen JH, Bleeker WK, Parren PW. Crosstalk between human IgG isotypes and murine effector cells. J Immunol 2012; 189(7):3430-8; PMID:22956577; http://dx.doi.org/10.4049/jimmunol.1200356
12. Hombach A, Hombach AA, Abken H. Adoptive immunotherapy with genetically engineered T cells:modification of the IgG1 Fc ‘spacer’ domain in the extracellular moiety of chimeric antigen receptors avoids ‘off-target’ activation and unintended initiation of an innate immune response. Gene Ther 2010; 17(10):1206-13; PMID:20555360; http://dx.doi.org/10.1038/gt.2010.91
13. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S, Daeron M. Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 2009; 113(16):3716-25; PMID:19018092; http://dx.doi.org/10.1182/blood-2008-09-179754
14. Jonsson F, Daeron M. Mast cells and company. Front Immunol 2012; 3:16; PMID:22566901; http://dx.doi.org/10.3389/fimmu.2012.00016
15. Anurathapan U, Chan RC, Hindi HF, Mucharla R, Bajgain P, Hayes BC, Fisher WE, Heslop HE, Rooney CM, Brenner MK, et al. Kinetics of tumor destruction by chimeric antigen receptor-modified T cells. Mol Ther 2014; 22(3):623-33; PMID:24213558; http://dx.doi.org/10.1038/mt.2013.262
16. Smith KG, Clatworthy MR. FcgammaRIIB in autoimmunity and infection:evolutionary and therapeutic implications. Nat Rev Immunol 2010; 10(5):328-43; PMID:20414206; http://dx.doi.org/10.1038/nri2762
17. Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, et al. A human memory T cell subset with stem cell-like properties. Nat Med 2011; 17(10):1290-7; PMID:21926977; http://dx.doi.org/10.1038/nm.2446
18. Wang X, Berger C, Wong CW, Forman SJ, Riddell SR, Jensen MC. Engraftment of human central memory-derived effector CD8+ T cells in immunodeficient mice. Blood 2011; 117(6):1888-98; PMID:21123821; http://dx.doi.org/10.1182/blood-2010-10-310599
19. Berger C, Jensen MC, Lansdorp PM, Gough M, Elliott C, Riddell SR. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J Clin Invest 2008; 118(1):294-305; PMID:18060041; http://dx.doi.org/10.1172/JCI32103
20. Xie Y, Akpinarli A, Maris C, Hipkiss EL, Lane M, Kwon EK, Muranski P, Restifo NP, Antony PA. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma. J Exp Med 2010; 207(3):651-67; PMID:20156973; http://dx.doi.org/10.1084/jem.20091921
21. Xu Y, Zhang M, Ramos CA, Durett A, Liu E, Dakhova O, Liu H, Creighton CJ, Gee AP, Heslop HE, et al. Closely related T-memory stem cells correlate with in vivo expansion of CAR.CD19-T cells and are preserved by IL-7 and IL-15. Blood 2014; 123(24):3750-9; PMID:24782509; http://dx.doi.org/10.1182/blood-2014-01-552174
22. Zeng R, Spolski R, Finkelstein SE, Oh S, Kovanen PE, Hinrichs CS, Pise-Masison CA, Radonovich MF, Brady JN, Restifo NP, et al. Synergy of IL-21 and IL-15 in regulating CD8+ T cell expansion and function. J Exp Med 2005; 201(1):139-48; PMID:15630141; http://dx.doi.org/10.1084/jem.20041057
23. Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR. Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo. Leukemia 2016; 30(2):492-500; PMID:26369987; http://dx.doi.org/10.1038/leu.2015.247
24. Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, et al. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest 2016; 126(6):2123-38; PMID:27111235; http://dx.doi.org/10.1172/JCI85309
25. Cieri N, Camisa B, Cocchiarella F, Forcato M, Oliveira G, Provasi E, Bondanza A, Bordignon C, Peccatori J, Ciceri F, et al. IL-7 and IL-15 instruct the generation of human memory stem T cells from naive precursors. Blood 2013; 121(4):573-84; PMID:23160470; http://dx.doi.org/10.1182/blood-2012-05-431718
26. Crompton JG, Sukumar M, Roychoudhuri R, Clever D, Gros A, Eil RL, Tran E, Hanada K, Yu Z, Palmer DC, et al. Akt inhibition enhances expansion of potent tumor-specific lymphocytes with memory cell characteristics. Cancer Res 2015; 75(2):296-305; PMID:25432172; http://dx.doi.org/10.1158/0008-5472.CAN-14-2277
27. Guest RD, Hawkins RE, Kirillova N, Cheadle EJ, Arnold J, O'Neill A, Irlam J, Chester KA, Kemshead JT, Shaw DM, et al. The role of extracellular spacer regions in the optimal design of chimeric immune receptors:evaluation of four different scFvs and antigens. J Immunother 2005; 28(3):203-11; PMID:15838376
28. Wilkie S, Picco G, Foster J, Davies DM, Julien S, Cooper L, Arif S, Mather SJ, Taylor-Papadimitriou J, Burchell JM, et al. Retargeting of human T cells to tumor-associated MUC1:the evolution of a chimeric antigen receptor. J Immunol 2008; 180(7):4901-9; PMID:18354214
29. Haso W, Lee DW, Shah NN, Stetler-Stevenson M, Yuan CM, Pastan IH, Dimitrov DS, Morgan RA, FitzGerald DJ, Barrett DM, et al. Anti-CD22-chimeric antigen receptors targeting B-cell precursor acute lymphoblastic leukemia. Blood 2013; 121(7):1165-74; PMID:23243285; http://dx.doi.org/10.1182/blood-2012-06-438002
30. Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR. Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells. Clin Cancer Res 2013; 19(12):3153-64; PMID:23620405; http://dx.doi.org/10.1158/1078-0432.CCR-13-0330
31. Kunkele A, Johnson AJ, Rolczynski LS, Chang CA, Hoglund V, Kelly-Spratt KS, Jensen MC. Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas-FasL-dependent AICD. Cancer Immunol Res 2015; 3(4):368-79; PMID:25576337; http://dx.doi.org/10.1158/2326-6066.CIR-14-0200
32. Vera JF, Hoyos V, Savoldo B, Quintarelli C, Giordano Attianese GM, Leen AM, Liu H, Foster AE, Heslop HE, Rooney CM, et al. Genetic manipulation of tumor-specific cytotoxic T lymphocytes to restore responsiveness to IL-7. Mol Ther 2009; 17(5):880-8; PMID:19259067; http://dx.doi.org/10.1038/mt.2009.34
33. Leen AM, Sukumaran S, Watanabe N, Mohammed S, Keirnan J, Yanagisawa R, Anurathapan U, Rendon D, Heslop HE, Rooney CM, et al. Reversal of tumor immune inhibition using a chimeric cytokine receptor. Mol Ther 2014; 22(6):1211-20; PMID:24732709; http://dx.doi.org/10.1038/mt.2014.47
34. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, Davis E, Wahl M, Nisitani S, Yamashiro J, Le Beau MM, et al. Prostate stem cell antigen:a cell surface marker overexpressed in prostate cancer. Proc Natl Acad Sci USA 1998; 95(4):1735-40; PMID:9465086
35. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005; 106(1):376-83; PMID:15755898; http://dx.doi.org/10.1182/blood-2004-12-4797
36. Fujisaki H, Kakuda H, Shimasaki N, Imai C, Ma J, Lockey T, Eldridge P, Leung WH, Campana D. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009; 69(9):4010-7; PMID:19383914; http://dx.doi.org/10.1158/0008-5472.CAN-08-3712
37. Lapteva N, Szmania SM, van Rhee F, Rooney CM. Clinical grade purification and expansion of natural killer cells. Crit Rev Oncog 2014; 19(1-2):121-32; PMID:24941378
38. Rasheed Z, Wang Q, Matsui W. Isolation of stem cells from human pancreatic cancer xenografts. J Vis Exp 2010 (43); PMID:20972397; http://dx.doi.org/10.3791/2169